Xiaoyan Si

1.3k total citations
78 papers, 893 citations indexed

About

Xiaoyan Si is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Xiaoyan Si has authored 78 papers receiving a total of 893 indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 39 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in Xiaoyan Si's work include Cancer Immunotherapy and Biomarkers (36 papers), Lung Cancer Treatments and Mutations (29 papers) and Lung Cancer Research Studies (18 papers). Xiaoyan Si is often cited by papers focused on Cancer Immunotherapy and Biomarkers (36 papers), Lung Cancer Treatments and Mutations (29 papers) and Lung Cancer Research Studies (18 papers). Xiaoyan Si collaborates with scholars based in China, United States and Germany. Xiaoyan Si's co-authors include Hanping Wang, Li Zhang, Xiaotong Zhang, Mengzhao Wang, Hong Ren, Lingyu Zhang, Lu Li, He Liu, Chungang Wang and Xiaotong Wu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Xiaoyan Si

74 papers receiving 883 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaoyan Si China 15 415 254 184 134 129 78 893
Li Huang China 20 183 0.4× 155 0.6× 329 1.8× 121 0.9× 107 0.8× 56 902
Kentaro Matsumoto Japan 16 208 0.5× 166 0.7× 240 1.3× 41 0.3× 129 1.0× 51 927
Keisuke Sugimoto Japan 12 234 0.6× 286 1.1× 232 1.3× 149 1.1× 165 1.3× 65 931
Jun Yong Lee South Korea 19 163 0.4× 68 0.3× 284 1.5× 202 1.5× 100 0.8× 94 1.1k
Wenrui Wu China 16 142 0.3× 105 0.4× 342 1.9× 41 0.3× 144 1.1× 35 732
Chun Han China 16 293 0.7× 168 0.7× 146 0.8× 47 0.4× 32 0.2× 57 744
Haiping Wang China 11 106 0.3× 183 0.7× 87 0.5× 57 0.4× 185 1.4× 33 519
Ying Che China 20 100 0.2× 80 0.3× 193 1.0× 63 0.5× 219 1.7× 57 1.2k
Dekun Wang China 21 169 0.4× 192 0.8× 561 3.0× 106 0.8× 106 0.8× 49 1.3k
Guoqiang Shao China 18 206 0.5× 182 0.7× 234 1.3× 24 0.2× 254 2.0× 71 888

Countries citing papers authored by Xiaoyan Si

Since Specialization
Citations

This map shows the geographic impact of Xiaoyan Si's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoyan Si with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoyan Si more than expected).

Fields of papers citing papers by Xiaoyan Si

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoyan Si. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoyan Si. The network helps show where Xiaoyan Si may publish in the future.

Co-authorship network of co-authors of Xiaoyan Si

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoyan Si. A scholar is included among the top collaborators of Xiaoyan Si based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoyan Si. Xiaoyan Si is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Yan, Q. Ping Dou, Xuefei Wu, et al.. (2025). Immune Checkpoint Inhibitor–Induced Ureteritis and Cystitis in Patients With Lung Cancer and Uterine Malignancies: A Case Series and Literature Review. Journal of Immunotherapy. 49(3). 108–114. 1 indexed citations
2.
Du, Yang, Ruili Pan, Xiaotong Zhang, et al.. (2024). Tocilizumab for advanced non-small cell lung cancer with concomitant inflammatory cachexia: A single-centre study.. Journal of Clinical Oncology. 42(16_suppl). 2647–2647. 2 indexed citations
3.
Si, Xiaoyan, Shafei Wu, Ruie Feng, et al.. (2024). Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort Study. Thoracic Cancer. 16(1). e15496–e15496. 1 indexed citations
4.
Li, Bowen, Ziqi Jia, Zhicheng Huang, et al.. (2023). Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report. Translational Lung Cancer Research. 12(11). 2322–2329. 2 indexed citations
5.
6.
Pan, Ruili, Minjiang Chen, Jing Zhao, et al.. (2022). Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis. Thoracic Cancer. 13(7). 1059–1066. 4 indexed citations
7.
Ni, Jun, Xiaoyan Si, Hanping Wang, Xiaotong Zhang, & Li Zhang. (2022). Prognostic biomarkers and immune cell infiltration characteristics in small cell lung cancer. SHILAP Revista de lepidopterología. 1(1). 18–24. 3 indexed citations
8.
He, Chun‐Xia, Xiaoyan Si, Li Zhang, Yan Xu, & Tao Qu. (2021). Immune checkpoint inhibitor–related epidermal necrolysis: A rare condition with poor prognosis. European Journal of Cancer. 145. 194–196. 7 indexed citations
9.
Ni, Jun, Xiaotong Zhang, Hanping Wang, et al.. (2021). Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period. Thoracic Cancer. 13(4). 539–548. 9 indexed citations
10.
Song, Peng, Dawei Yang, Xiaolong Cui, et al.. (2020). NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score. SHILAP Revista de lepidopterología.
11.
Wang, Hanping, Jiaxin Zhou, Xiaoxiao Guo, et al.. (2020). Use of glucocorticoids in the management of immunotherapy‐related adverse effects. Thoracic Cancer. 11(10). 3047–3052. 17 indexed citations
12.
Si, Xiaoyan, Jinwan Wang, Ying Cheng, et al.. (2020). A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 12. 3863580889–3863580889. 11 indexed citations
13.
Song, Peng, Hanping Wang, Xiaoxia Cui, et al.. (2020). Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients. Thoracic Cancer. 11(6). 1647–1654. 19 indexed citations
14.
Ye, Jin, et al.. (2020). Plasma Long Non-Coding RNA RP11-438N5.3 as a Novel Biomarker for Non-Small Cell Lung Cancer. SHILAP Revista de lepidopterología. 2 indexed citations
15.
Ni, Jun, Han‐Ping Wang, Xiaoyan Si, et al.. (2020). Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study. Thoracic Cancer. 11(7). 1869–1875. 2 indexed citations
16.
Si, Xiaoyan, Ruili Pan, Shaohua Ma, et al.. (2020). Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer. Thoracic Cancer. 12(3). 357–363. 18 indexed citations
17.
Si, Xiaoyan, Hanping Wang, Xiaotong Zhang, et al.. (2020). Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum‐pemetrexed: The first report of two cases. Thoracic Cancer. 11(8). 2339–2342. 3 indexed citations
18.
Song, Peng, Hanping Wang, Xiaoxia Cui, et al.. (2020). Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients. Thoracic Cancer. 11(6). 1621–1632. 66 indexed citations
19.
20.
Si, Xiaoyan, et al.. (1990). [Chemical constituents in the stem of Premna crassa Hand. -Mazz].. PubMed. 15(8). 487–8, 512. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Li Huang Breakdown of academic impact, for papers by Kentaro Matsumoto Breakdown of academic impact, for papers by Keisuke Sugimoto Breakdown of academic impact, for papers by Jun Yong Lee Breakdown of academic impact, for papers by Wenrui Wu Breakdown of academic impact, for papers by Chun Han Breakdown of academic impact, for papers by Haiping Wang Breakdown of academic impact, for papers by Ying Che Breakdown of academic impact, for papers by Dekun Wang Breakdown of academic impact, for papers by Guoqiang Shao
Rankless by CCL
2026